What are the needs for transplantation treatment in vitiligo, and how good is it?

Archives of Dermatology

Volumn 140, Issue 10, 2004, Pages 1273-1274

  Olsson, Mats J ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPSIN;

ANAMNESIS; DISEASE MARKER; EDITORIAL; FOLLOW UP; HUMAN; LONG TERM CARE; MELANOCYTE; PRIORITY JOURNAL; TRANSPLANTATION; TREATMENT INDICATION; TREATMENT OUTCOME; VITILIGO;

HUMANS; LASER SURGERY; MELANOCYTES; VITILIGO;

EID: 5444234085     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.10.1273     Document Type: Editorial

References (11)

1. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1:58.
2. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16:208-214.
3. Fain PR, Gowan K, LaBerge GS, et al. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet. 2003;72:1560-1564.
4. Olsson MJ, Juhlin L. Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol. 2002;147:893-904.
5. Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, et al. Immunopolarization of CD4* and CD8* T cells to Type 1-like is associated with melanocyte loss in human vitiligo. Lab invest. 2003;83:683-695.
6. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998;188:1203-1208.
7. Gottumukkala RV, Waterman EA, Herd LM, et al. Autoantibodies in vitiligo patients recognize multiple domains of the melanin-concentrating hormone receptor. J Invest Dermatol. 2003;121:765-770.
8. Kemp EH, Waterman EA, Gawkrodger DJ, et al. Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo. Clin Exp Immunol. 2001;124:509-515.
9. Hedstrand H, Ekwall O, Olsson MJ, et al. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem. 2001;276:35390-35395.
10. Kemp EH, Waterman EA, Gawkrodger DJ, et al. Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo. J Invest Dermatol. 1999;113:267-271.
11. Beck AJ, Phillips J, Smith-Thomas L, et al. Development of a plasmapolymerized surface suitable for the transplantation of keratinocyte-melanocyte cocultures for patients with vitiligo. Tissue Eng. 2003;9:1123-1131.